Nivolumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09035 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 18 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | non-cutaneous melanoma | KG + DL |
| 2 | epithelioid cell melanoma | KG + DL |
| 3 | superficial spreading melanoma | KG + DL |
| 4 | nodular malignant melanoma | KG + DL |
| 5 | malignant melanoma of the mucosa | KG + DL |
| 6 | acral lentiginous melanoma (disease) | KG + DL |
| 7 | balloon cell malignant melanoma | KG + DL |
| 8 | amelanotic skin melanoma | KG + DL |
| 9 | lentigo maligna melanoma | KG + DL |
| 10 | CDK4 linked melanoma | KG + DL |
| 11 | eyelid melanoma | KG + DL |
| 12 | scrotum melanoma | KG + DL |
| 13 | choroideremia | KG + DL |
| 14 | choroidal dystrophy, central areolar | KG + DL |
| 15 | intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency | KG + DL |
| 16 | Richter syndrome | KG + DL |
| 17 | metastatic neoplasm | KG + DL |
| 18 | malignant spiradenoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.